Whalesbook
Jefferies ka kehna hai ki Cohance Life Sciences mein abhi aur girne ka risk hai, isliye unhone rating ko 'hold' se badal kar 'underperform' kar diya hai. Price target bhi ₹340 se kam karke ₹300 kar diya gaya hai. Haalanki stock April 24 ke baad se lagbhag 33% bhaga tha, naye CEO Umang Vohra ke aane se bhi market mein jo optimism thi, use Jefferies thoda doubt kar raha hai.
Q4 Ke Numbers Ne Kiya Pareshaan
Is downgrade ka sabse bada reason company ka Q4 results hai, jo expectations se kaafi neeche aaye hain. Sabhi business segments mein girawat dikhi hai, khaas kar Specialty Chemicals mein toh kaafi bura haal raha. EBITDA margins pe bhi kaafi pressure chal raha hai. Is wajah se, Jefferies ne FY27 aur FY28 ke liye EPS estimates ko 14-17% tak kam kar diya hai. Stock abhi ₹478-₹485 ke aas paas trade kar raha tha, lekin Jefferies ko lagta hai ki ismein abhi kaafi neeche jaane ki scope hai.
Valuation Aur Sector Ka Kya Scene Hai?
Cohance Life Sciences ki market cap ₹18,300 se ₹18,600 crore ke beech mein hai. Iska P/E ratio lagbhag 58 se 130 tak chal raha hai, jo ki Indian specialty chemicals sector ke hisaab se kaafi zyada hai. Sector toh bohot acche se grow kar raha hai, par Cohance ki performance is trend se alag chal rahi hai. MarketsMojo ne bhi is stock ko 'Sell' rating di hui hai.
Management Aur Operational Issues
Sabse badi pareshani hai management mein instability. Umang Vohra, jo pehle Cipla ke CEO reh chuke hain, woh ek saal mein company ke teesre CEO bane hain. Ye baar baar leadership change strategy aur execution par sawaal khade karta hai. Iske alawa, company ki Telangana facility ko US FDA ne Form 483 diya tha jisme six observations thi. Promoter ke lagbhag 100% shares pledged hain, jo ki ek bada risk factor hai.
Aage Ka Outlook
Jefferies ka maan'na hai ki FY27 bhi company ke liye mushkil hi rahega, aur recovery shayad second half mein hi ho paaye. Hallanki company ka pipeline strong hai, par current financial pressures aur leadership issues growth ke liye bade hurdles hain.